文献速递细菌感染、耐药与抗菌药物医院感染防控

头孢地尔作为ICU碳青霉烯耐药革兰阴性菌感染的挽救治疗

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.
PubMed 文献 · Clin Infect Dis · 2021-01-01

Ten critically ill patients with either bacteremia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, or New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae received cefiderocol.…

要点

  • 头孢地尔对碳青霉烯耐药鲍曼不动杆菌等革兰阴性菌有体外活性
  • 2例出现微生物学失败,需前瞻性研究进一步评估

主要发现

  • 所有菌株最低抑菌浓度≤2 μg/mL。

关键数值与推荐

  • 所有菌株对头孢地尔的最低抑菌浓度≤2 μg/mL。

临床怎么用

  • 对于ICU中由碳青霉烯耐药鲍曼不动杆菌、嗜麦芽窄食单胞菌或产NDM型金属β-内酰胺酶肺炎克雷伯菌引起的血流感染或呼吸机相关性肺炎,头孢地尔可作为挽救治疗选择。

局限性

  • 本文为病例系列,样本量小,需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ten critically ill patients with either bacteremia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, or New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae received cefiderocol. All strains had minimum inhibitory concentration ≤2 μg/mL. Thirty-day clinical success and survival rates were 70% and 90%, respectively. Two patients had a microbiological failure. Future prospective studies are warranted.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients. Clin Infect Dis. 2021. PMID: 32941593. doi:10.1093/cid/ciaa1410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。